专利快速检索-快速检索全球专利，免费商用专利数据库-IPRDB

1. 发明申请

WO2017148854A1 IGFBP-7 AS A MARKER IN PREECLAMPSIA 审中-公开
标题翻译： IGFBP-7作为前列腺炎的标志物
公开(公告)号：WO2017148854A1
公开(公告)日：2017-09-08
申请号：PCT/EP2017/054484
申请日：2017-02-27
申请人： ROCHE DIAGNOSTICS GMBH , F. HOFFMANN-LA ROCHE AG , ROCHE DIAGNOSTICS OPERATIONS, INC.
发明人： HUND, Martin , KAISER, Edelgard Anna , WIENHUES-THELEN, Ursula-Henrike , BLOCK, Dirk , KARL, Johann
IPC分类号： G01N33/68 , G06F19/10
CPC分类号： G01N33/689 , G01N33/6893 , G01N2333/4703 , G01N2333/4745 , G01N2800/368 , G01N2800/52 , G01N2800/60 , G16B99/00
摘要： The present invention relates to a method for diagnosing preeclampsia or a preeclampsia-related condition in a pregnant subject. The preeclampsia-related condition can be eclampsia, HELLP syndrome or proteinuria. Said method is based on the measurement of the amount of the biomarker IGFBP-7 (Insulin-like Growth Factor Binding Protein 7) in a sample from the subject and on the comparison of the measured amount to a reference. Also encompassed by the present invention are methods for assessing the severity of preeclampsia or a preeclampsia-related condition and methods for monitoring a preeclampsia or a preeclampsia-related condition in a pregnant subject. The present invention further relates to the use of the biomarker IGFBP-7 or of an agent that specifically binds to IGFBP-7 in a sample from a pregnant subject for diagnosing, for monitoring or for assessing the severity of preeclampsia or a preeclampsia-related condition. Optionally, sFlt-1, Endoglin, PIGF are determined. Finally, the present invention relates to a device adapted to carry out the method of the present invention.
摘要翻译：本发明涉及用于诊断怀孕受试者中先兆子痫或先兆子痫相关病症的方法。先兆子痫相关病症可以是子痫，HELLP综合征或蛋白尿。所述方法基于对来自受试者的样品中生物标志物IGFBP-7（胰岛素样生长因子结合蛋白7）的量的测量以及将测量量与参比进行比较。本发明还包括用于评估先兆子痫或先兆子痫相关病症的严重程度的方法以及用于监测怀孕受试者中先兆子痫或先兆子痫相关病症的方法。本发明进一步涉及生物标志物IGFBP-7或特异性结合来自怀孕受试者的样品中的IGFBP-7的试剂用于诊断，监测或评估先兆子痫或先兆子痫相关病症的严重程度。任选地，确定sFlt-1，内皮糖蛋白，PIGF。最后，本发明涉及一种适于执行本发明方法的装置。

2. 发明申请

WO2017060525A1 IGFBP7 FOR PREDICTION OF RISK OF AKI WHEN MEASURED PRIOR TO SURGERY 审中-公开
标题翻译： IGFBP7用于预测手术前测量的AKI风险
公开(公告)号：WO2017060525A1
公开(公告)日：2017-04-13
申请号：PCT/EP2016/074206
申请日：2016-10-10
申请人： ROCHE DIAGNOSTICS GMBH , F. HOFFMANN-LA ROCHE AG , ROCHE DIAGNOSTICS OPERATIONS, INC.
发明人： HORSCH, Andrea , KLAPPERICH, Birgit , BLOCK, Dirk , ENGEL, Alfred , KARL, Johann , KIENTSCH-ENGEL, Rosemarie , MANUILOVA, Ekaterina , RABE, Christina , RUTZ, Sandra , SOUKUPOVA, Monika , WIENHUES-THELEN, Ursula-Henrike , KASTNER, Peter , KAIER, Anna, Edelgard
IPC分类号： G01N33/68 , G01N33/74
CPC分类号： G01N33/68 , G01N33/6893 , G01N33/74
摘要： The present invention relates to a method for predicting the risk of a patient to suffer from acute kidney injury (AKI) during or after a surgical procedure or after administration of a contrast medium. The method is based on the determination of the level of the biomarker IGFBP7(Insulin-like Growth Factor Binding Protein 7) in a body fluid sample obtained from the patient prior to said surgical procedure or prior to said administration of a contrast medium. Further, the present invention relates to a method for predicting the risk of a patient to suffer from acute kidney injury (AKI) based on the determination of the amount of the biomarker IGFBP7(Insulin-like Growth Factor Binding Protein 7) and Cystatin C in a body fluid sample obtained from the patient. The present invention further encompasses kits and devices adapted to carry out the methods of the present invention.
摘要翻译：本发明涉及一种用于预测患者在外科手术期间或之后或施用造影剂后患有急性肾损伤（AKI）的风险的方法。该方法基于在所述外科手术之前或在所述施用造影剂之前从患者获得的体液样品中测定生物标志物IGFBP7（胰岛素样生长因子结合蛋白7）的水平。此外，本发明涉及一种基于测定生物标志物IGFBP7（胰岛素样生长因子结合蛋白7）和半胱氨酸蛋白酶抑制剂C量的方法来预测患者患有急性肾损伤（AKI）的风险的方法从患者获得的体液样品。本发明还包括适用于实施本发明方法的试剂盒和装置。

3. 发明申请

WO2017216387A1 CIRCULATING ANGIOPOIETIN-2 (ANG-2) FOR THE PREDICTION OF RECURRENCE OF ATRIAL FIBRILLATION 审中-公开
标题翻译：循环血管生成素-2（ANG-2）用于预测心房颤动的复发
公开(公告)号：WO2017216387A1
公开(公告)日：2017-12-21
申请号：PCT/EP2017/064970
申请日：2017-06-19
申请人： ROCHE DIAGNOSTICS GMBH , F. HOFFMANN-LA ROCHE AG , ROCHE DIAGNOSTICS OPERATIONS, INC.
发明人： ANDRES, Herbert , BLOCK, Dirk , KARL, Johann , KASTNER, Peter , WIENHUES-THELEN, Ursula-Henrike , LATINI, Roberto , MASSON, Serge , ZIEGLER, André , KAISER, Edelgard , PALME, Stefan , THOMAS, Markus , BARLERA, Simona
IPC分类号： G01N33/68
摘要： The present invention relates to a method for predicting the risk of recurrence of Atrial Fibrillation in a subject based on determining the amount of the biomarker Angiopoietin-2 (Ang-2) and optionally of at least one further biomarker in a sample from the subject. The present invention also contemplates a method of diagnosing Atrial Fibrillation in a subject suspected to suffer from Atrial Fibrillation based on determining the amount of the biomarker Angiopoietin-2 (Ang-2) and optionally of at least one further biomarker in a sample from the subject. Further envisaged are devices adapted to carry out the method of the present invention.
摘要翻译：本发明涉及基于确定生物标志物血管生成素-2（Ang-2）和任选地至少一种其他药物的量来预测受试者心房颤动复发风险的方法生物标志物来自受试者的样品。本发明还考虑基于确定来自受试者的样品中的生物标志物血管生成素-2（Ang-2）和任选地至少一种另外的生物标志物的量来诊断怀疑患有心房颤动的受试者中的心房颤动的方法。进一步设想适合于实施本发明的方法的设备。

4. 发明申请

WO2017182446A1 SOLUBLE ST2 FOR THE IDENTIFICATION OF PROGRESSORS TO LVH IN THE GENERAL POPULATION 审中-公开
标题翻译：可溶性ST2用于鉴定普通人群LVH进展者
公开(公告)号：WO2017182446A1
公开(公告)日：2017-10-26
申请号：PCT/EP2017/059137
申请日：2017-04-18
申请人： ROCHE DIAGNOSTICS GMBH , F. HOFFMANN-LA ROCHE AG , ROCHE DIAGNOSTICS OPERATIONS, INC. , INSTITUT LORRAIN DU COEUR ET DES VAISSEAUX LOUIS MATHIEU
发明人： BLOCK, Dirk , WIENHUES-THELEN, Ursula-Henrike , ZAUGG, Christian , ZIEGLER, André , ZANNAD, Faiez , ROSSIGNOL, Patrick
IPC分类号： G01N33/68
摘要： The present invention relates to a method of identifying a subject who is at risk of progressing to left ventricular hypertrophy (LVH), comprising the steps of measuring the amount of the biomarker soluble ST2 and comparing the thus measured amount to a reference. Further encompassed by the present invention are kits and devices adapted to carry out the method of the present invention.
摘要翻译：本发明涉及鉴定有发展成左心室肥大（LVH）风险的受试者的方法，其包括测量生物标记物可溶性ST2的量并将如此测量的相当于一个参考。本发明进一步涵盖的是适合于实施本发明方法的试剂盒和装置。

5. 发明申请

WO2016066698A1 BIOMARKERS FOR RISK PREDICTION OF MORTALITY 审中-公开
标题翻译：风险预测的生物标志物
公开(公告)号：WO2016066698A1
公开(公告)日：2016-05-06
申请号：PCT/EP2015/075012
申请日：2015-10-28
申请人： ROCHE DIAGNOSTICS GMBH , F. HOFFMANN-LA ROCHE AG , ROCHE DIAGNOSTICS OPERATIONS, INC.
发明人： LATINI, Roberto , MASSON, Serge , BLOCK, Dirk , ZAUGG, Christian , DIETERLE, Thomas , KAISER, Edelgard , KARL, Johann , ROLNY, Vinzent , WIENHUES-THELEN, Ursula-Henrike
IPC分类号： G01N33/68
CPC分类号： G01N33/6893 , G01N2333/4703 , G01N2333/4712 , G01N2333/4745 , G01N2333/475 , G01N2333/495 , G01N2333/50 , G01N2333/515 , G01N2333/58 , G01N2333/70525 , G01N2800/325
摘要： The present invention relates to a method for predicting the risk of a subject of rapidly progressing to chronic heart failure and/or of hospitalization due to chronic heart failure and/ or death. The method is based on the determination of at least one bio marker selected from the group consisting of a BNP-type peptide, IGFBP7 (IGF binding protein 7), a cardiac Troponin, soluble ST2 (sST2), FGF-23 (Fibroblast Growth Factor 23), and Growth Differentiation Factor 15 (GDF-15), in a sample of a subject. The method may further encompass the assessment of the presence or absence of (i) abnormal midwall fractional shortening or (ii) left ventricular hypertrophy. Further envisaged by the present invention are devices adapted to carry out the present invention.
摘要翻译：本发明涉及一种用于预测快速进展为慢性心力衰竭和/或由于慢性心力衰竭和/或死亡引起的住院治疗的受试者的风险的方法。该方法基于至少一种选自由BNP型肽，IGFBP7（IGF结合蛋白7），心肌肌钙蛋白，可溶性ST2（sST2），FGF-23（成纤维细胞生长因子 23）和生长分化因子15（GDF-15）。该方法还可以包括（i）异常中壁部分缩短或（ii）左心室肥大的存在或不存在的评估。本发明进一步设想的是适用于实施本发明的设备。

6. 发明申请

WO2015113889A1 BIOMARKERS FOR RISK ASSESSMENT AND TREATMENT MONITORING IN HEART FAILURE PATIENTS GUIDED BY NATRIURETIC PEPTIDES 审中-公开
标题翻译：风险评估和治疗心脏缺陷患者的生物标志物由NATRIURETIC PEPTID指导
公开(公告)号：WO2015113889A1
公开(公告)日：2015-08-06
申请号：PCT/EP2015/051239
申请日：2015-01-22
申请人： ROCHE DIAGNOSTICS GMBH , F. HOFFMANN-LA ROCHE AG , ROCHE DIAGNOSTICS OPERATIONS, INC.
发明人： BLOCK, Dirk , BRUNNER, Hanspeter , WIENHUES-THELEN, Ursula-Henrike , ZAUGG, Christian , DIETERLE, Thomas , MITCHELL, Cheryl , UBBY, Johan , SANDERS-VAN WIJK, Sandra
IPC分类号： G01N33/68
CPC分类号： G01N33/6893 , G01N33/62 , G01N33/66 , G01N33/6869 , G01N33/6887 , G01N33/70 , G01N33/723 , G01N33/84 , G01N2333/4737 , G01N2333/5412 , G01N2333/58 , G01N2333/78 , G01N2333/805 , G01N2800/325 , G01N2800/347 , G01N2800/52
摘要： The present invention relates to a method for identifying a patient who is eligible to an intensification of heart failure therapy. Furthermore, the present invention relates to a method for optimizing BNP-type peptide guided heart failure therapy. The methods are based on the measurement of the level of at least one marker in a sample from a patient who has heart failure and who receives BNP-type peptide guided heart failure therapy. Further envisaged by the present invention are kits and devices adapted to carry out the present invention.
摘要翻译：本发明涉及一种用于识别符合心力衰竭治疗强化的患者的方法。此外，本发明涉及一种优化BNP型肽引导性心力衰竭治疗的方法。该方法基于来自患有心力衰竭并且接受BNP型肽引导的心力衰竭治疗的患者的样品中至少一个标记物的水平的测量。本发明进一步设想的是适用于实施本发明的试剂盒和装置。

7. 发明申请

WO2015144767A1 IGFBP7 FOR DIAGNOSING DIASTOLIC DYSFUNCTION 审中-公开
标题翻译： IGFBP7用于诊断软组织损伤
公开(公告)号：WO2015144767A1
公开(公告)日：2015-10-01
申请号：PCT/EP2015/056418
申请日：2015-03-25
申请人： ROCHE DIAGNOSTICS GMBH , F. HOFFMANN-LA ROCHE AG , ROCHE DIAGNOSTICS OPERATIONS, INC.
发明人： KARL, Johann , WIENHUES-THELEN, Ursula-Henrike , BLOCK, Dirk , ZAUGG, Christian , BRUNNER, Hans-Peter , JANUZZI, James , ZIEGLER, André , BRAZ, Julian , DIETERLE, Thomas , KAISER, Edelgard
IPC分类号： G01N33/68
CPC分类号： G01N33/6893 , G01N33/6887 , G01N2333/47 , G01N2800/325
摘要： The present invention relates to a method for diagnosing and/or grading diastolic dysfunction or at least one structural or functional abnormality associated with diastolic dysfunction. The method comprises measuring the level of IGFBP7 (Insulin like growth factor binding protein 7) and, optionally, the level of at least one further marker in a patient suffering from heart failure, and comparing the level to a reference level. Further envisaged is a method of monitoring diastolic function in a patient suffering from heart failure. Also encompassed by the present invention are kits and devices adapted to carry out the method of the present invention.
摘要翻译：本发明涉及一种用于诊断和/或分级舒张功能障碍或与舒张功能障碍相关的至少一种结构或功能异常的方法。该方法包括测量患有心力衰竭的患者中IGFBP7（胰岛素样生长因子结合蛋白7）的水平和任选的至少一个其他标志物的水平，并将该水平与参考水平进行比较。进一步设想的是监测患有心力衰竭的患者的舒张功能的方法。本发明还包括适用于实施本发明方法的试剂盒和装置。

8. 发明申请

WO2015014794A1 USE OF ALPHA-CRYSTALLIN B (CRYAB) IN THE ASSESSMENT OF HEART FAILURE 审中-公开
标题翻译：使用AL-CRYSTALLIN B（CRYAB）评估心力衰竭
公开(公告)号：WO2015014794A1
公开(公告)日：2015-02-05
申请号：PCT/EP2014/066178
申请日：2014-07-28
申请人： F. HOFFMANN-LA ROCHE AG , ROCHE DIAGNOSTICS GMBH , ROCHE DIAGNOSTICS OPERATIONS, INC. , THE GOVERNING COUNCIL OF THE UNIVERSITY OF TORONTO
发明人： WIENHUES-THELEN, Ursula-Henrike , HESS, Georg , BLOCK, Dirk , HUEDIG, Hendrik , EMILI, Andrew , GRAMOLINI, Anthony , LIU, Peter , MACLENNAN, David , ARAB, Sara
IPC分类号： G01N33/68
CPC分类号： G01N33/6893 , G01N33/6887 , G01N2333/4712 , G01N2800/325
摘要： The invention relates to a method for assessing heart failure in vitro comprising the steps of measuring in a sample the concentration of the marker CRYAB, of optionally measuring in the sample the concentration of one or more other marker(s) of heart failure selected from the group consisting of a natriuretic peptide marker, a cardiac troponin marker, and a marker of inflammation, and of assessing heart failure by comparing the concentration determined in for CRYAB and the concentration(s) determined for the optionally one or more other marker to the concentration of this marker or these markers as established in a reference population. Also disclosed are the use of CRYAB as a marker protein in the assessment of heart failure, a marker combination comprising CRYAB and a kit for measuring CRYAB.
摘要翻译：本发明涉及体外评估心力衰竭的方法，其包括以下步骤：在样品中测量标记物CRYAB的浓度，任选地在样品中测量一种或多种其他标记物（心脏肌钙蛋白标志物和炎症标志物组成的组的心力衰竭患者的心力衰竭评估以及通过比较CRYAB中测定的浓度和任选测定的（一种或多种）一个或多个其他标志物与参考群体中建立的该标志物或这些标志物的浓度。还公开了在评估心力衰竭中使用CRYAB作为标志物蛋白，包含CRYAB和用于测量CRYAB的试剂盒的标志物组合。

9. 发明申请

WO2014072500A1 TNT BASED DIAGNOSIS OF PAROXYSMAL ATRIAL FIBRILLATION 审中-公开
标题翻译：基于TNT的PAROXYSMAL ATRIAL FIBRILLATION的诊断
公开(公告)号：WO2014072500A1
公开(公告)日：2014-05-15
申请号：PCT/EP2013/073476
申请日：2013-11-11
申请人： ROCHE DIAGNOSTICS GMBH , F. HOFFMANN-LA ROCHE AG , BLOCK, Dirk , LATINI, Roberto , MASSON, Serge , WIENHUES-THELEN, Ursula-Henrike , ZAUGG, Christian , ZIEGLER, Andre
发明人： BLOCK, Dirk , LATINI, Roberto , MASSON, Serge , WIENHUES-THELEN, Ursula-Henrike , ZAUGG, Christian , ZIEGLER, Andre
IPC分类号： G01N33/68
CPC分类号： G01N33/6893 , G01N33/6869 , G01N33/6887 , G01N2333/4712 , G01N2333/4737 , G01N2333/4745 , G01N2333/5412 , G01N2333/58 , G01N2800/326 , G01N2800/52
摘要： The present invention relates to a method for diagnosing a recent paroxysmal atrial fibrillation. The method is based on the determination of the at least one marker selected from the group consisting of a cardiac Troponin, NT-proBNP (N-terminal prohormone of brain natriuretic peptide), hsCRP, IL-6 (Interleukin-6) and IGFBP7 (Insulin like growth factor binding protein 7) in a sample from the subject, and on the comparison of the, thus, determined amount(s) with a reference amount (reference amounts). Further, the present invention relates to a method for identifying a subject being susceptible to anticoagulation therapy. Further envisaged are systems, reagents and kits used in performing the methods disclosed herein.
摘要翻译：本发明涉及一种诊断近期阵发性房颤的方法。该方法基于选自心肌肌钙蛋白，NT-proBNP（脑钠尿肽的N-末端激素原），hsCRP，IL-6（白细胞介素-6）和IGFBP7（来自受试者的样品中的胰岛素样生长因子结合蛋白7）以及由此确定的量与参考量（参考量）的比较。此外，本发明涉及用于鉴定易于抗凝治疗的受试者的方法。进一步设想的是用于执行本文公开的方法的系统，试剂和试剂盒。

10. 发明申请

WO2014040759A1 IDENTIFICATION OF PATIENTS WITH ABNORMAL FRACTIONAL SHORTENING 审中-公开
标题翻译：鉴别患有异常分娩的患者
公开(公告)号：WO2014040759A1
公开(公告)日：2014-03-20
申请号：PCT/EP2013/056706
申请日：2013-03-28
申请人： ROCHE DIAGNOSTICS GMBH , F. HOFFMANN-LA ROCHE AG , BLOCK, Dirk , MASSON, Serge , WIENHUES-THELEN, Ursula-Henrike , ZAUGG, Christian , LATINI, Roberto
发明人： BLOCK, Dirk , MASSON, Serge , WIENHUES-THELEN, Ursula-Henrike , ZAUGG, Christian , LATINI, Roberto
IPC分类号： G01N33/68
CPC分类号： G01N33/6887 , A61B5/055 , A61B8/0883 , G01N33/82 , G01N2333/4703 , G01N2333/4706 , G01N2333/4712 , G01N2333/50 , G01N2333/78 , G01N2800/32 , G01N2800/329 , G01N2800/50
摘要： The present invention relates to a method for assessing whether a subject shall be subjected to an imaging based diagnostic assessment. The method is based on the determination of the amount(s) of a cardiac Troponin and/or Fibroblast Growth Factor 23 (FGF-23) in a sample from the subject, and on the comparison of the, thus, determined amount(s) with a reference amount (reference amounts). The present invention also relates to a system for performing an assessment whether a subject shall be subjected to an imaging based diagnostic assessment and to reagents and kits used in performing the methods disclosed herein. Moreover, the present invention is directed to a method for predicting the risk of mortality and/or of a cardiovascular event. Also encompassed is a method for diagnosing an early stage of LVH in a subject having a preserved left ventricular ejection.
摘要翻译：本发明涉及一种用于评估受试者是否应进行基于成像的诊断评估的方法。该方法基于来自受试者的样品中心肌肌钙蛋白和/或成纤维细胞生长因子23（FGF-23）的量的测定，以及因此确定的量（s）具有参考量（参考量）。本发明还涉及一种用于执行评估受试者是否应进行基于成像的诊断评估的系统以及用于执行本文所公开的方法的试剂和试剂盒。此外，本发明涉及一种用于预测死亡风险和/或心血管事件风险的方法。还包括用于诊断具有保留的左心室射血的受试者的LVH的早期阶段的方法。

你已经成功收藏专利！

检索式保存成功!

IPRDB

热门服务

关于我们

友情链接

联系方式